PropThink: Oral Remodulin Rejection A Broader Problem; Continue To Sell

[ACN Newswire] – By Jake KingUnited Therapeutics Corporation (NASDAQ:UTHR) announced after hours on Tuesday that it’s application for an oral formulation of Remodulin (treprostinil) received a Complete Response Letter … more

View todays social media effects on UTHR

View the latest stocks trending across Twitter. Click to view dashboard